Nephros Inc
NEPH- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001196298
No open-market purchases or sales by Nephros Inc insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 33
- 13F valueReported value at the end of Q2 2026
- $19.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NEPH, Q2 2026
No superinvestor reported holding NEPH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nephros Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 30, 2024 (view filing) | May 28-30 | 2 days | Amron Arthur HDirector | PPurchase | +5.00K | $2.23 | +$11.2K | +5.1%103.5K after | 2 lots |
| May 16, 2024 (view filing) | May 16 | Same day | Banks Robert R. Jr.President and CEO | PPurchase | +50.0K | $2.24 | +$112.0K | +250.0%70.0K after | |
| Mar 14, 2024 (view filing) | Mar 12 | 2 days | Amron Arthur HDirector | PPurchase | +7.00K | $2.45 | +$17.1K | New position7.00K after | |
| Dec 11, 2023 (view filing) | Dec 7 | 4 days | Banks Robert R. Jr.President and CEO | PPurchase | +18.0K | $2.20 | +$39.6K | +900.0%20.0K after | |
| Aug 15, 2023 (view filing) | Aug 14-15 | 1 day | Banks Robert R. Jr.President and CEO | PPurchase | +2.00K | $1.68 | +$3.36K | New position2.00K after | 2 lots |
| Aug 23, 2021 (view filing) | Aug 20 | 3 days | Lobo Wesley S.Chief Marketing Officer | PPurchase | +1.00K | $7.92 | +$7.92K | +2.5%41.6K after | |
| Aug 19, 2021 (view filing) | Aug 18 | 1 day | Gwydir TomDirector | PPurchase | +5.00K | $7.64 | +$38.2K | +82.9%11.0K after | |
| Aug 18, 2021 (view filing) | Aug 17-18 | 1 day | Astor AndrewPresident & CEO | PPurchase | +5.00K | $7.72 | +$38.6K | +6.9%78.0K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nephros Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wexford Capital LP | 3,600,552 | $12.9M | 1.76% | 00.0% | Unchanged |
| Topline Capital Management, LLC | 535,698 | $1.91M | 0.50% | −46,269−8.0% | Reduced |
| Vanguard Capital Management LLC | 198,643 | $709.2K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 128,915 | $460.2K | 0.00% | +18,000+16.2% | Added |
| Cornerstone Capital, Inc. | 128,700 | $459.5K | 0.04% | 00.0% | Unchanged |
| Bard Associates Inc | 118,003 | $421.3K | 0.09% | −3,199−2.6% | Reduced |
| Renaissance Technologies LLC | 77,504 | $276.7K | 0.00% | −21,896−22.0% | Reduced |
| Geode Capital Management, LLC | 70,263 | $250.9K | 0.00% | −2,662−3.7% | Reduced |
| Mesirow Financial Investment Management, Inc. | 60,000 | $214.2K | 0.00% | −60,000−50.0% | Reduced |
| HighTower Advisors, LLC | 59,710 | $213.2K | 0.00% | 00.0% | Unchanged |